BioSystems International and Northeastern University have announced that they have signed a Licence Agreement for The University’s "Monoclonal antibody based biomarker discovery and development platform".
The monoclonal antibody based biomarker discovery and validation platform was developed by scientists at Pfizer Fresnes Laboratories and Northeastern University.
Pfizer retains rights to use the technology for its programs and transferred all other rights to Northeastern University.
Now, Northeastern University grants BSI an exclusive, world-wide license for biomarker and drug target discovery, validation, development and commercialization for medical and all other commercial applications, including veterinary, agricultural, food industry and biohazard fields.
According to Prof. Barry Karger, James A. Waters Chair of Analytical Chemistry at Northeastern University, director of the Barnett Insitute, and co-founder of BSI, "The licensed technology that has been developed offers a major opportunity to discover and validate trace level disease specific biomarkers."
"BSI will exploit its power in the biomedical and pharmaceutical domain while the Barnett Institute will advance the technology."
According to Laszlo Takacs, President and CEO of BioSystems International, "With the monoclonal antibody based biomarker discovery and validation technology license, BSI’s already rich intellectual property portfolio is significantly enhanced."
"Now we have a strong position to secure technology advantage over competition in the area of monoclonal antibody based proteomics and its application in the healthcare industry."
"BSI is looking forward to applying the licensed and in-house technologies to establish partnerships and internal programs for the discovery of novel cancer and chronic disease diagnostics."